Is Broadcom Stock Overvalued?
The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…
Sell
47
BEAM Quote, Financials, Valuation and Earnings
Last price:
$26.38
Seasonality move
:
-20.08%
Day range:
$25.59 - $27.05
52-week range:
$20.84 - $49.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.18x
P/B ratio:
2.76x
Volume:
1.6M
Avg. volume:
1.1M
1-year change:
-2.55%
Market cap:
$2.2B
Revenue:
$377.7M
EPS (TTM):
-$1.76
Analysts' Opinion
-
Consensus RatingBeam Therapeutics has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 7 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $47.93, Beam Therapeutics has an estimated upside of 81.62% from its current price of $26.39.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $23.00 representing 12.85% downside risk from its current price of $26.39.
Fair Value
-
According to the consensus of 14 analysts, Beam Therapeutics has 81.62% upside to fair value with a price target of $47.93 per share.
BEAM vs. S&P 500
-
Over the past 5 trading days, Beam Therapeutics has overperformed the S&P 500 by 8.96% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Beam Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Beam Therapeutics revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Beam Therapeutics reported revenues of $14.3M.
Earnings Growth
-
Beam Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Beam Therapeutics reported earnings per share of -$1.17.
Enterprise value:
1.3B
EV / Invested capital:
--
Price / LTM sales:
6.18x
EV / EBIT:
--
EV / Revenue:
3.60x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-8.66x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-10.97%
Net Income Margin (TTM):
-41.07%
Return On Equity:
-16.62%
Return On Invested Capital:
-16.62%
Operating Margin:
-746.4%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $92M | $81.6M | $349.6M | $17.2M | $14.3M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$313M | -$398.3M | -$182.7M | -$108.3M | -$106.5M | |
| EBITDA | -$300.1M | -$379.7M | -$160.8M | -$103.1M | -$101M | |
| Diluted EPS | -$4.54 | -$4.17 | -$1.76 | -$1.22 | -$1.17 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $208.7M | $941.4M | $1.1B | $1B | $945.5M | |
| Total Assets | $278.3M | $1.2B | $1.4B | $1.3B | $1.2B | |
| Current Liabilities | $47.5M | $101.4M | $238.9M | $220.4M | $166.2M | |
| Total Liabilities | $78.2M | $302.7M | $635.8M | $511.6M | $380.1M | |
| Total Equity | $200.1M | $853.8M | $714.5M | $778.9M | $791.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $93.5M | -$353.5M | -$135.8M | -$89.8M | -$88.1M | |
| Cash From Investing | -$652.3M | $87.2M | $156.8M | -$10.2M | $24.7M | |
| Cash From Financing | $101.1M | $274.7M | $38M | $36.8M | $1.3M | |
| Free Cash Flow | $39.5M | -$391.9M | -$145.4M | -$97.7M | -$89.7M | |
BEAM
Sector
Market Cap
$2.2B
$47.5M
Price % of 52-Week High
53.31%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
-1.66%
-0.74%
1-Year Price Total Return
-2.55%
-34.04%
Beta (5-Year)
--
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$25.85
200-day SMA
Buy
Level
$25.50
Bollinger Bands (100)
Buy
Level
23.5 - 27.4
Chaikin Money Flow
Buy
Level
4.9M
20-day SMA
Sell
Level
$27.22
Relative Strength Index (RSI14)
Sell
Level
48.59
ADX Line
Neutral
Level
17.18
Williams %R
Neutral
Level
-58.6197
50-day SMA
Buy
Level
$26.35
MACD (12, 26)
Sell
Level
-0.13
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
33.7M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.3321)
Sell
CA Score
(Annual)
Level (-0.413)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.2269)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
Stock Forecast FAQ
In the current month, BEAM has received 7 Buy ratings 7 Hold ratings, and 0 Sell ratings. The BEAM average analyst price target in the past 3 months is $47.93.
-
Where Will Beam Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Beam Therapeutics share price will rise to $47.93 per share over the next 12 months.
-
What Do Analysts Say About Beam Therapeutics?
Analysts are divided on their view about Beam Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Beam Therapeutics is a Sell and believe this share price will drop from its current level to $23.00.
-
What Is Beam Therapeutics's Price Target?
The price target for Beam Therapeutics over the next 1-year time period is forecast to be $47.93 according to 14 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is BEAM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Beam Therapeutics is a Leans Bullish. 7 of 14 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of BEAM?
You can purchase shares of Beam Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Beam Therapeutics shares.
-
What Is The Beam Therapeutics Share Price Today?
Beam Therapeutics was last trading at $26.38 per share. This represents the most recent stock quote for Beam Therapeutics. Yesterday, Beam Therapeutics closed at $26.39 per share.
-
How To Buy Beam Therapeutics Stock Online?
In order to purchase Beam Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
